We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+56.7%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$347M
AUM Growth
+$107M
Cap. Flow
+$4.3M
Cap. Flow %
1.24%
Top 10 Hldgs %
48.52%
Holding
95
New
16
Increased
11
Reduced
34
Closed
8

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$7.34M
2
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$6.6M
3
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$6.16M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.48M
5
LQDA icon
Liquidia Corp
LQDA
+$4.17M

Top Sells

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$4.64M
2
DXCM icon
DexCom
DXCM
+$4.37M
3
CRBP icon
Corbus Pharmaceuticals
CRBP
+$4.31M
4
CGEN icon
Compugen
CGEN
+$3.47M
5
ASND icon
Ascendis Pharma A/S
ASND
+$2.68M

Sector Composition

Rank Sector Weight
1 Healthcare 88.26%
2 Financials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNCA
51
DELISTED
Genocea Biosciences, Inc.
GNCA
$1.21M 0.35%
524,664
-17,900
-3% -$41.2K
PRVL
52
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$1.12M 0.32%
75,000
– –
APLS
53
DELISTED
Apellis Pharmaceuticals
APLS
$1.1M 0.32%
33,554
-20,500
-38% -$658K
AUTL
54
Autolus Therapeutics
AUTL
$506M
$1.03M 0.3%
64,235
-155,565
-71% -$1.73M
KRTX
55
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$1.03M 0.3%
9,231
+3,000
+48% +$261K
STIM icon
56
Neuronetics
STIM
$164M
$957K 0.28%
495,772
– –
NTUS
57
DELISTED
Natus Medical Inc
NTUS
$936K 0.27%
42,900
– –
HOOK
58
DELISTED
HOOKIPA Pharma
HOOK
$931K 0.27%
+8,012
New +$781K
CRBP icon
59
Corbus Pharmaceuticals
CRBP
$177M
$907K 0.26%
3,602
-21,308
-86% -$4.31M
ASMB icon
60
Assembly Biosciences
ASMB
$526M
$830K 0.24%
2,964
– –
AVTX icon
61
Avalo Therapeutics
AVTX
$997M
$827K 0.24%
+110
New +$799K
SLNO
62
DELISTED
Soleno Therapeutics
SLNO
$827K 0.24%
+24,833
New +$1.08M
STRO icon
63
Sutro Biopharma
STRO
$416M
$826K 0.24%
10,644
+6,644
+166% +$638K
SYBX
64
DELISTED
Synlogic
SYBX
$819K 0.24%
26,906
-6,476
-19% -$207K
MORF
65
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$812K 0.23%
30,000
-7,000
-19% -$131K
MDGL icon
66
Madrigal Pharmaceuticals
MDGL
$11.9B
$747K 0.22%
6,600
-7,000
-51% -$688K
SCPH
67
DELISTED
scPharmaceuticals
SCPH
$736K 0.21%
+100,000
New +$878K
TCRR
68
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$709K 0.2%
46,183
-32,603
-41% -$376K
MASI
69
DELISTED
Masimo
MASI
$684K 0.2%
3,000
– –
ZYME icon
70
Zymeworks
ZYME
$1.73B
$651K 0.19%
18,039
-13,961
-44% -$514K
GMDA
71
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$640K 0.18%
140,000
-8,781
-6% -$40.3K
CBAY
72
DELISTED
Cymabay Therapeutics
CBAY
$578K 0.17%
+165,600
New +$478K
CYPH
73
Cypherpunk Technologies Inc
CYPH
$78M
$575K 0.17%
+27,500
New +$590K
INGN icon
74
Inogen
INGN
$178M
$533K 0.15%
15,000
-8,000
-35% -$337K
RNTX
75
Rein Therapeutics
RNTX
$61.1M
$531K 0.15%
+22,500
New +$367K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return

DAFNA Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, DAFNA Capital Management held 95 positions worth $347M, up 45% from $240M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

DAFNA Capital Management's Q2 2020 filing shows 16 new, 11 increased, 34 reduced and 8 closed positions. Its largest new stake was Immunomedics Inc: 250,905 shares worth $8.89M. The largest sale was AtriCure, an estimated $4.64M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 92% a quarter earlier, followed by Financials.

  • DAFNA Capital Management's largest Q2 2020 buy was Immunomedics Inc: 250,905 shares worth $8.89M.
  • DAFNA Capital Management added most to Dicerna Pharmaceuticals, Inc. in Q2 2020, an estimated $6.6M increase.
  • DAFNA Capital Management's biggest Q2 2020 reduction was AtriCure, cutting an estimated $4.64M.
  • DAFNA Capital Management fully exited Epizyme, Inc in Q2 2020, selling an estimated $1.64M.
  • DAFNA Capital Management's ten largest holdings make up 49% of its $347M portfolio in Q2 2020.
  • DAFNA Capital Management opened 16 new positions and closed 8 in Q2 2020.
  • DAFNA Capital Management's portfolio value rose 45% quarter-over-quarter to $347M.

Based on DAFNA Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.